Dr. Daniel Kopans

Breast
Dr. Daniel Kopans: Will the USPSTF heed science on breast screening?
The U.S. Preventive Services Task Force (USPSTF) has begun a review of its guidelines on breast screening. Dr. Daniel Kopans believes the task force should heed the established science on mammography and recommend screening of women in their 40s.
January 28, 2021
2016 10 11 13 31 21 852 Am Second Opinion 400
Breast
Kopans: New NEJM paper offers rehash on 'overdiagnosis'
In this Second Opinion article, Dr. Daniel Kopans of Massachusetts General Hospital comments on a paper on breast screening by Welch et al published this week in the New England Journal of Medicine. The Welch paper is based on false assumptions and makes the same mistakes as a 2012 paper on the same topic, according to Kopans.
October 12, 2016
2016 10 11 13 31 21 852 Am Second Opinion 400
Breast
Kopans: JAMA Oncology paper misinterprets DCIS data
Just how deadly is ductal carcinoma in situ (DCIS)? A paper by Narod et al published on August 20 in JAMA Oncology suggests that the best way to deal with DCIS is simply to ignore it, rather than treating it aggressively. But such conclusions represent a dangerous misinterpretation of the actual data, according to Dr. Daniel Kopans.
August 23, 2015
2013 04 29 15 33 22 49 Kopans Daniel 200 20130429223516
Home
A response to Harding et al
The ploy used by Harding et al in their new study is classic. Explain why using your approach is scientifically unsupportable, and then go ahead and use it claiming there is no alternative.
July 5, 2015
Dr. Daniel Kopans from Massachusetts General Hospital.
Breast
Dr. Daniel Kopans: Topol ignores facts on mammography
In this Second Opinion article, Dr. Daniel Kopans of Massachusetts General Hospital offers a rebuttal of a May 6 column by cardiologist Dr. Eric Topol that calls for an end to routine mammography screening. Dr. Kopans believes the column misinterprets the facts about breast screening.
May 6, 2015
2013 06 03 12 02 47 211 Second Opinion Am 200
Breast
Dr. Daniel Kopans: On the draft USPSTF breast screening guidelines
In this Second Opinion article, Dr. Daniel Kopans offers his perspective on the release this week of new guidelines on screening mammography from the U.S. Preventive Services Task Force (USPSTF) -- guidelines that he believes will restrict access to mammography.
April 20, 2015
2013 06 03 12 02 47 211 Second Opinion Am 200
Breast
Kopans: Attacks on mammography are part of coordinated effort
In this Second Opinion article, breast imaging expert Dr. Daniel Kopans of Massachusetts General Hospital offers his perspective on the rising number of research studies with negative findings on screening mammography.
April 27, 2014
2013 06 03 12 02 47 211 Second Opinion Am 200
Breast
Kopans: Breast cancer overdiagnosis grossly exaggerated
In this Second Opinion article, breast imaging expert Dr. Daniel Kopans offers his rebuttal of a study published last November in the New England Journal of Medicine, which raised questions about the value of screening mammography and claimed that a third of detected breast cancers represent "overdiagnosis."
April 29, 2013
2013 04 29 15 33 22 49 Kopans Daniel 200 20130429223516
Breast
Shock and awe over JAMA editorial
The University of California, San Francisco researchers who authored this week's JAMA editorial on screening have disregarded the facts regarding the value of screening mammography, according to Dr. Daniel Kopans, who shares his view in this AuntMinnie Second Opinion.
October 21, 2009
2009 06 23 14 37 33 976 Second Opinion Am
Breast
DBT: Not a panacea, but promising technology is unfairly panned
The debate over the relative value of digital breast tomosynthesis (DBT) for cancer screening continues with Dr. Daniel Kopans, founder of the breast imaging division at Massachusetts General Hospital in Boston, who offers an opinion on the technology.
October 29, 2007
2007 10 01 09 05 35 706
Page 1 of 1
Top Stories
Breast Cancer
Molecular Imaging
FES-PET guides second-line therapy decisions in breast cancer
FES-PET/CT results led to therapeutic management changes in 37.8% of patients.
Fda Button 400
Radiation Oncology/Therapy
Recalls stable for radiation oncology tools despite tech advancements
Minnie Cast Thumbnail (25)
Ultrasound
Ultrasound MinnieCast, Episode 17: Elastography holds promise toward expanded role
Radiation oncology medical physicist Michael Grams, MD, holds a device called a tungsten collimator that divides a conventional radiation beam into submillimeter-wide beamlets.
Radiation Oncology/Therapy
Minibeam radiotherapy performs well in first clinical trial
Free webinar for radiology leaders
Sponsor Content
Free webinar for radiology leaders
More in Home
FES-PET guides second-line therapy decisions in breast cancer
By Will Morton
FES-PET/CT results led to therapeutic management changes in 37.8% of patients.
September 18, 2026
Breast Cancer
Recalls stable for radiation oncology tools despite tech advancements
By Amerigo Allegretto
While radiation oncology devices using AI or machine learning are increasingly entering the market, recalls may be plateauing.
September 18, 2026
Fda Button 400
Ultrasound MinnieCast, Episode 17: Elastography holds promise toward expanded role
By Amerigo Allegretto
David Fetzer, MD, discusses current applications and issues in the world of elastography.
September 18, 2026
Minnie Cast Thumbnail (25)
Minibeam radiotherapy performs well in first clinical trial
By Will Morton
The technique delivers very high doses of radiation through closely spaced, extremely narrow beams.
September 17, 2026
Radiation oncology medical physicist Michael Grams, MD, holds a device called a tungsten collimator that divides a conventional radiation beam into submillimeter-wide beamlets.
USPSTF names radiologist to task force; ACR responds
By Amerigo Allegretto
Dennis Wulfeck, MD, has 33 years of experience in diagnostic imaging, and his appointment to the task force has the support of the ACR.
September 17, 2026
Capitol Hill Government 400
Individual specialization may drive IR procedure complexity
By Amerigo Allegretto
Practice- and radiologist-level IR specializations showed associations with greater procedural complexity.
September 17, 2026
Interventional Radiology 400
AI boosts brain aneurysm detection on CT angiography
By Will Morton
AI preferentially detected smaller aneurysms (< 3 mm), while radiologists more often identified larger aneurysms (3 to 5 mm and > 5 mm).
September 17, 2026
Ai Brain
ASTRO issues first radiation therapy guideline for bladder cancer
By AuntMinnie.com staff writers
Bladder preservation should be presented as a curative treatment option alongside radical cystectomy.
September 16, 2026
Astro1
LLM on par with head-and-neck subspecialists in analyzing MRI reports
By Amerigo Allegretto
GPT-5-Thinking yields similar diagnostic accuracy compared to subspecialists focusing on orbital and head-and-neck MRI.
September 16, 2026
Mri Brain Head 400
CCTA links neighborhood income to atherosclerosis
By Will Morton
The relationship between socioeconomic disparities and imaging-defined coronary atherosclerosis on CCTA has not been fully understood.
September 15, 2026
Heart 1
Chest CT muscle attenuation predicts future bone density loss
By Will Morton
Muscle and bone loss commonly coexist with aging, but potential links between paraspinal muscle and thoracic vertebral bone mineral density loss remain poorly understood
September 15, 2026
Study overview. (A) Volumetric segmentation of the paraspinal musculature was performed for 1,316 participants. (B) Manual segmentation was performed, the results were compared with the volumetric segmentation results, and the Dice score and the intersection over union were calculated. (C) The three-dimensional segmentations from T1 through T10 were individually extracted and combined into a single volume for analyses. (D) Muscle volume and median muscle attenuation were derived from the segmentation volumes. (E) Analyses were performed to assess the correlation of the paraspinal muscle attenuation and volume with the bone mineral density and the ability to predict vertebral fractures. NIFTI = Neuroimaging Informatics Technology Initiative, 3D = three-dimensional.
Curium gets FDA approval for Lu-177 injection for GEP-NETs
By AuntMinnie.com staff writers
The radioligand therapy delivers targeted radiation to GEP-NETs by binding to somatostatin receptors expressed on these tumors.
September 15, 2026
Approved Stamp 400
Page 1 of 250
Next Page